Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

Looking Into Intercept Pharmaceuticals's Return On Capital Employed

Intercept Pharmaceuticals (NASDAQ:ICPT) brought in sales totaling $92.40 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 898.9%, resulting in a loss of $36.28 million. Intercept Pharmaceuticals collected $92.83 million in revenue during Q3, but reported earnings showed a $3.63 million loss.

Why Is ROCE Significant?

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.